Medizone International, Inc. Board of Directors
David Esposito – Chairman of the Board
David Esposito served as President and General Manager of Phadia US Inc. from 2009-2011 (Phadia US, was the US division of privately held, Phadia AB, a premier global specialty diagnostics company prior to its acquisition by Thermo Fisher Scientific for $3.5B USD in August of 2011). David Esposito joined Phadia US as the senior vice president of sales and marketing in 2009 after a successful career in sales, marketing and commercial strategy with Merck and Co., Inc. David led several initiatives to accelerate the sales growth of Phadia’s core product ImmunoCAP during his early tenure in the assignment. David became the President and General Manager in Sept of 2009.
Under David’s leadership, Phadia US delivered double digit growth of the company’s core products ImmunoCAP® (specific IgE testing) and EliA® (autoimmune testing) for several years. In addition, David spearheaded the development of several commercial initiatives to support Phadia’s leadership in the area of bringing breakthrough diagnostics to the US marketplace for the allergy and autoimmune segments. The successful growth of the company culminated in the sale to Thermo Fisher Scientific for $3.5B USD in August of 2011. David served as Vice President for US Commercial Operations within the Specialty Diagnostics Group of Thermo Fisher Scientific for two years before leaving to pursue other professional interests.
Before joining Phadia, David played several key leadership roles for Merck & Co. Inc in the US market. David led the marketing team for Singulair®, Merck’s largest branded product at the time. He developed innovative, multi-channel marketing programs to continue to accelerate growth in a highly competitive and crowded asthma and allergy marketplace. As Merck embarked on a journey to create an “industry leading new commercial model” in 2007, David was called on to play a key role in developing and leading the customer facing arm of the new model. Through David’s skill in balancing strategy with realistic tactical execution, the initial work on the model drove increased sales, increased customer trust and value measures and increased employee engagement while reducing headcount and overall operational expenses by 35%. As a result, Merck’s new commercial model was rolled out nationally and David was moved into the pivotal role of leading the overall commercial strategy for the US Division at a time of unprecedented change in the pharmaceutical industry.
David’s leadership skills and ability to develop and articulate strategy with clear tactical discipline to drive execution were enhanced and nurtured during his 4 years at West Point and his subsequent leadership assignments in the US Army Infantry. As an Airborne Ranger Infantry officer, David led a rifle platoon of 39 men with the 101st Airborne Division in Operation Desert Shield/Storm (1990-1991) through several combat operations and was recognized with a Bronze Star for combat action on 24 February 1991.
David was born and raised in northern New Jersey. David, his wife Tracy, and their four active children, have enjoyed living in numerous areas of the country as a result of relocations for key assignments in the marketplace. They presently call Kalamazoo, MI “home.” Outside of work, David is very active with his family coaching sports teams, spending time outdoors and doing charitable work. In addition, David is the inventor/developer of a series of programs entitled Character Creates Opportunity® designed to improve the character development of children, adolescents and adults. Most recently, his conversation games Abundant Harvest® and Face to Face™ are being actively marketed to families, schools, counseling centers, and faith-based programs to support more effective communication and action planning in dealing with the often difficult and complex situations we find ourselves in today. David and Tracy are the founders and sponsors of Harvest Time Partners Foundation; a charitable organization supporting youth and young adults in pursuit of character building opportunities.
David A. Dodd – Chief Executive Officer & Board Member
David Dodd has successfully led the growth and development of companies within life sciences, establishing leadership positions within targeted markets, developing growing employment opportunities and achieving significant shareholder value. He has more than 35 years of executive experience in the healthcare/life sciences industry, successfully guiding the growth and development of such businesses. In addition, Mr. Dodd has been a highly active member of civic, charitable, industry and economic growth organizations, both within the USA and internationally.
From April 2013 until August 2017, Mr. Dodd served as President, CEO of Aeterna Zentaris Inc. (NASDAQ: “AEZS”; www.aezsinc.com); he also served as Chairman of the Board from May 2014 until May 2016. He joined the Company following a series of disappointing clinical development programs that resulted in a Company stock price decrease in excess of 90%. During Mr. Dodd’s tenure at AEZS, a new, commercial-oriented growth strategy was developed, the Company embarked on a comprehensive restructuring, new corporate governance policies were implemented, including a restructuring of the Board of Directors and the Company focused on rapidly transforming into a growth-oriented, commercially based specialty biopharmaceutical company. As a result, Aeterna Zentaris has it’s first New Drug Application (“NDA”) currently under active review by the FDA, with a PDUFA date of December 30, 2017.
Mr. Dodd has served on a number of public and private company boards with such companies as PNP Therapeutics, Aruna Biomedical and GeoVax, a company developing novel vaccines to prevent diseases such as Zika virus, hemoragghic fevers (Ebola, Marburg, Lassa), HIV/AIDS, as well as immune-therapies for oncology and Hepatitis B. He continues to serve as Chairman of GeoVax.
From October 2006 to April 2009, Mr. Dodd served as Non-executive Chairman of Stem Cell Sciences Plc., based in Cambridge, UK, which developed and commercialized research products and services in support of stem cell biological research and development. A publicly-traded company, dual-listed on the LSE:AIM and ASX exchanges, the business was successfully sold to StemCells, Inc., in April 2009.
Mr. Dodd served as President, Chief Executive Officer and Director of Serologicals Corporation (Nasdaq: SERO) from June 2000 to its acquisition by Millipore Corporation in July 2006. Mr. Dodd led a successful transformation of the business, significantly expanding the operations globally and competitively. During his leadership, Serologicals was developed from a value of $85 million in June 2000 to the $1.5 billion acquisition by Millipore.
Previously, Mr. Dodd served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and Chairman of its subsidiary Unimed Pharmaceuticals, Inc. This operation successfully developed from an annual revenue base in 1995 of $100 million to $500 million in 2000, becoming a leader in its respective therapeutic areas, while enterprise value increased from approximately $100 million to $2 billion.
In addition to his successful leadership service within the for-profit sector, Mr. Dodd has served in ongoing leadership roles in support of growing and developing the not-for-profit sector and the overall healthcare and life sciences industry. His service includes/has included serving on the Board of Directors of the Harvard Business School, Health Industry Alumni Association; on the Board of the Medical University of South Carolina Foundation Horizon Project (Charleston, SC); as an advisor to the South Carolina Research Authority (SCRA); as an advisor to Georgia Research Alliance (GRA); as Chairman, GaBio; Chairman of the Metro Atlanta Biosciences Council; Member of the Advisory Board of the Institute of Bioengineering & Biosciences at GaTech; various advisory roles to the Georgia Research Alliance; various roles within the international BIO (Biotechnology Industry Organization); Chairman, American Foundation for Suicide Prevention; the Carter Center Board of Advisors and, many other roles, both domestic and international, in support of the growth and development of the healthcare/life sciences industry. Mr. Dodd received the prestigious Oglethorpe Sword from the British-American Business Group in recognition of his consistent success in forging business relationships between Georgia and the UK. Also, Mr. Dodd was previously selected by the prestigious MacArthur Foundation to be a member of a select 10-person, internationally recruited team to establish the guidelines for a “Genius Grant” in the research area of Women’s Health.
Mr. Dodd earned both a Bachelors of Science and Masters of Science degrees from Georgia State University, and he successfully completed the Advanced Management Program at Harvard Business School. In 2011, Mr. Dodd was recognized by Georgia State University, awarding him the Distinguished Alumni Achievement Award for his business achievements and civic contributions.
Michael E. Shannon, M.A.,M.Sc.,M.D. – President & Director of Medical Affairs, Board Member
Dr. Shannon received his medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years.
He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces.
In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years.
In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General’s office. His assignment being to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004.
Dr. Shannon then served on a special assignment to the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully held in Toronto in December of 2007.
Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University.
Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2002. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed responsibility for medical affairs. In October 2008, he was additionally appointed the President of the Canadian Foundation for Global Health.
Vincent C. Caponi – Board Member
Mr. Caponi currently serves as the Executive Chairman of the Board of St. Vincent Health and as a Senior Vice President of Ascension Health Alliance. Until July 2013, Mr. Caponi had served as the Chief Executive Officer of St. Vincent Health. He grew the St. Vincent Health ministry to a 22-hospital system serving central and southern Indiana. St. Vincent Health is one of Indiana’s largest employers.
Ascension Health of St. Louis, Missouri – the sponsor of St. Vincent Health – is the nation’s largest Catholic non-profit health system with 130 hospitals located in eight states.
Steve Meyer – Board Member
Steve Meyer is the recent president & chief executive officer and director of Welch Allyn, Inc., a privately-held, developer, manufacturer, and marketer of frontline care medical devices and diagnostic solutions headquartered in Skaneateles Falls, New York. A native of Michigan, Meyer joined Welch Allyn in 1981 as a sales representative in Detroit. Over 30+ years, Steve held a series of senior leadership roles in a variety of areas from international sales and marketing to product development, operations, and general management. As President and CEO, Steve navigated Welch Allyn during a time of substantial industry change, developing and executing a new strategy, restructuring the business, engaging more deeply with customers, and becoming more acquisitive. In September of 2015 Welch Allyn achieved a premium valuation in its merger with Hill-Rom, Inc. (NYSE: HRC).
Currently, Steve serves on several boards including Paragon Medical, Inc., a supplier of surgical instruments, implantable components, and design and development services to the medical device marketplace, where he is Chairman; SRC Ventures, Inc. a wholly owned subsidiary of SRC that facilitates bringing innovative technologies to the commercial and international markets. He is an executive advisor to Beecken Petty O’Keefe & Company, a private equity management firm which focuses on the healthcare industry, and is an advisor to Medical Distribution Solutions, Inc., a leading publishing and content company in the healthcare business. He is a past board member of TIDI Medical Products, during which TIDI was acquired by J.H. Whitney & Company followed by RoundTable Healthcare Partners, both private equity firms. He is a Trustee of Alma College in Michigan, recently serving as board chair.
In addition to his Board activities, Steve started and is Managing Director of River Marsh Capital, LLC, a firm investing primarily in healthcare developments which enhance and improve health, and providing corporate advisory services to companies, private equity, and venture firms.
Steve is a past board member of Medical Device Manufacturers Association (MDMA), AdvaMed, Health Industry Distributors Foundation, and American Academy of Family Physicians Foundation (AAFP). He served as a board member and chair of MedTech (New York’s Medical Technology Association), and board member and president of Health Industry Manufacturers Marketing Council (HMMC). He received the Leonard Burke Award for Mentoring from HMMC and Outstanding Service Award from AAFP. In 2012 Steve received the Medical Industry Award of Excellence from the Health Industry Distributors Association for his continuing contributions to the health care industry. In 2016, Steve was conferred an Honorary Doctor of Letters degree from Alma College.
Steve holds a Bachelor of Science in Biology from Alma College and earned his Master’s of Business Administration from the William E. Simon Graduate School of Business at the University of Rochester, New York.